These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32090461)

  • 1. Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report.
    Mannon RB; Morris RE; Abecassis M; Axelrod D; Bala S; Friedman GS; Heeger PS; Lentine KL; Loupy A; Murphy B; Nickerson P; Sarwal M; O'Doherty I; Spear N; Karpen SR
    Am J Transplant; 2020 Jun; 20(6):1495-1502. PubMed ID: 32090461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public-private partnerships in transplant drug development.
    Albrecht R; Papadopoulos EJ; Campbell M; Daniels S; Kluetz PG; Parekh A; Wang Y
    Am J Transplant; 2020 Feb; 20(2):377-381. PubMed ID: 31553120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualifying a novel clinical trial endpoint (iBOX) predictive of long-term kidney transplant outcomes.
    Klein A; Loupy A; Stegall M; Helanterä I; Kosinski L; Frey E; Aubert O; Divard G; Newell K; Meier-Kriesche HU; Mannon RB; Dumortier T; Aggarwal V; Podichetty JT; O'Doherty I; Gaber AO; Fitzsimmons WE;
    Am J Transplant; 2023 Oct; 23(10):1496-1506. PubMed ID: 37735044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes.
    Klein A; Loupy A; Stegall M; Helanterä I; Kosinski L; Frey E; Aubert O; Divard G; Newell K; Meier-Kriesche HU; Mannon R; Dumortier T; Aggarwal V; Podichetty JT; O'Doherty I; Gaber AO; Fitzsimmons WE
    Transpl Int; 2023; 36():11951. PubMed ID: 37822449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients.
    Ettenger R; Albrecht R; Alloway R; Belen O; Cavaillé-Coll MW; Chisholm-Burns MA; Dew MA; Fitzsimmons WE; Nickerson P; Thompson G; Vaidya P
    Am J Transplant; 2018 Mar; 18(3):564-573. PubMed ID: 29288623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.
    Stegall MD; Troy Somerville K; Everly MJ; Mannon RB; Gaber AO; First MR; Agashivala N; Perez V; Newell KA; Morris RE; Sudan D; Romero K; Eremenco S; Mattera M; Spear N; Porter AC; O'Doherty I
    Am J Transplant; 2019 Mar; 19(3):625-632. PubMed ID: 30549395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualification of biomarkers for drug development in organ transplantation.
    Burckart GJ; Amur S; Goodsaid FM; Lesko LJ; Frueh FW; Huang SM; Cavaille-Coll MW
    Am J Transplant; 2008 Feb; 8(2):267-70. PubMed ID: 18093264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Getting immunosuppression just right: the role of clinical biomarkers in predicting patient response post solid organ transplantation.
    Brunet M; Millán O
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1467-1479. PubMed ID: 34607521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.
    Christians U; Klawitter J; Klawitter J; Brunner N; Schmitz V
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):175-200. PubMed ID: 21241200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers as a tool for management of immunosuppression in transplant patients.
    Wieland E; Olbricht CJ; Süsal C; Gurragchaa P; Böhler T; Israeli M; Sommerer C; Budde K; Hartmann B; Shipkova M; Oellerich M
    Ther Drug Monit; 2010 Oct; 32(5):560-72. PubMed ID: 20814352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell immune monitoring in organ transplantation.
    Dinavahi R; Heeger PS
    Curr Opin Organ Transplant; 2008 Aug; 13(4):419-24. PubMed ID: 18685339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exclusive Drug Labeling Rights as a New Incentive for Contribution to a Communal Biomarker Resource.
    Shore D
    Am J Law Med; 2018 Nov; 44(4):607-626. PubMed ID: 30802165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?
    Rebollo-Mesa I; Nova-Lamperti E; Mobillo P; Runglall M; Christakoudi S; Norris S; Smallcombe N; Kamra Y; Hilton R; ; Bhandari S; Baker R; Berglund D; Carr S; Game D; Griffin S; Kalra PA; Lewis R; Mark PB; Marks S; Macphee I; McKane W; Mohaupt MG; Pararajasingam R; Kon SP; Serón D; Sinha MD; Tucker B; Viklický O; Lechler RI; Lord GM; Hernandez-Fuentes MP
    Am J Transplant; 2016 Dec; 16(12):3443-3457. PubMed ID: 27328267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in solid organ transplantation.
    Gieser G; Harigaya H; Colangelo PM; Burckart G
    Clin Pharmacol Ther; 2011 Aug; 90(2):217-20. PubMed ID: 21772300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction.
    OʼConnell PJ; Kuypers DR; Mannon RB; Abecassis M; Chadban SJ; Gill JS; Murphy B; Nickerson PW; Schold JD; Stock PG; Seron D; Alloway RR; Bromberg JS; Budde K; Jordan SC; Legendre C; Lefaucheur C; Sarwall M; Segev DL; Stegall MD; Tullius SG; Wong G; Woodle ES; Ascher N; Morris RE
    Transplantation; 2017 Jul; 101(7):1527-1534. PubMed ID: 28207630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical biomarker qualification.
    Sauer JM; Porter AC;
    Exp Biol Med (Maywood); 2018 Feb; 243(3):222-227. PubMed ID: 29171289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current topics in immunotherapy and the role of the pharmacist on a solid organ transplant service.
    Shaefer MS
    Pharmacotherapy; 1991; 11(6):136S-141S. PubMed ID: 1771138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.